STL Volume 21 Number 4
3 POSTS 0 COMMENTSPurchase PDF for $2.79
Update on Drugs and Drug News: July-August 2016
Update on Bilastine tablet (Blexten™), Ixekizumab SC injection (Talz®), Wound care gel (Lasercyn™ gel), Ceftaroline fosamil (Teflaro®), Nivolumab + ipilimumab (Opdivo® + Yervoy®), PDT for actinic keratosis (Ameluz® gel + BF-RhodoLED®)
Frontal Fibrosing Alopecia
Frontal fibrosing alopecia has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. It has distinctive features and associations which distinguish it from LPP. Discussion includes familial or genetic factors, etiology, and trials.
Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa
Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Discussion includes, safety and efficacy in clinical trials.